Hosted on MSN
Why I wouldn't touch Novavax with a 10-foot pole
Novavax faces plenty of uncertainty related to a deal it signed with a larger company. The biotech's pipeline doesn't look that exciting either. 10 stocks we like better than Novavax › Novavax (NASDAQ ...
The MarketWatch News Department was not involved in the creation of this content. -- Non-exclusive license allows for development by Pfizer to utilize Matrix-M(R) for up to two disease areas with its ...
Novavax’s modeled fair value has been reset to US$13.78 from US$13.11, a small move that still matters if you are tracking how assumptions are shifting. Behind that change, recent Street research ...
Novavax, Inc. (NASDAQ:NVAX) on Thursday revealed preclinical data from the H5N1 avian pandemic influenza vaccine candidate. Leveraging Novavax’s recombinant, protein-based nanoparticle technology and ...
Peer-reviewed data shows Novavax's H5N1 vaccine candidate demonstrated immunogenicity against currently circulating variants following either single or two-dose administration Potential for single ...
Novavax Inc. NVAX shares are up on Thursday following the company’s announcement of its fourth-quarter and full-year 2025 financial results. Earnings Novavax reported fourth-quarter earnings of 11 ...
We recently compiled a list of the 9 High Growth Small Cap Stocks That Are Profitable. Novavax, Inc. stands second on our list of high growth stocks. TheFly reported on January 20 that BofA raised its ...
GAITHERSBURG, Md., Jan. 20, 2026 /PRNewswire/ -- Novavax, Inc. has entered into a license agreement with Pfizer for use of Novavax's Matrix-M ® adjuvant. Under the terms of the agreement, Pfizer will ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results